Huge potential for this pre-revenue diagnostic company $ASEP.C recently finalized an exclusive licensing arrangement with the University of British Columbia for a patented and potentially groundbreaking AI-driven technology that enables early and accurate diagnosis of sepsis, which is also a major contributing factor in COVID-19 and influenza morbidity.
The global market for sepsis diagnosis is expected to reach US$771-$975 million by 2026, with more recent reports stating a US$1.3 billion target by 2032. This represents a massive growth opportunity for $ASEP. If the company is able to capture a share of this diagnostic market, its growth potential is exponential.
$ASEP.C is currently trading at $.3 and the company is valued at an MCAP of $16.84 million.
https://www.hospimedica.com/covid-19/articles/294791483/groundbreaking-ai-driven-sepsis-diagnosis-technology-could-guide-personalized-treatment-for-hospitalized-covid-19-patients.html